Silexion Therapeutics Corp
Clinical-stage biotech developing RNAi therapies for KRAS-driven pancreatic cancer.
SLXN | US
Overview
Corporate Details
- ISIN(s):
- KYG1281K1141 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 12 ABBA HILLEL ROAD, 5250606 RAMAT GAN
- Website:
- https://www.moringaac.com/
Description
Silexion Therapeutics Corp. is a clinical-stage biotechnology company that discovers and develops proprietary treatments for KRAS-driven cancers, with a primary focus on pancreatic cancer. The company pioneers RNA interference (RNAi)-based therapies and advanced delivery systems to address significant therapeutic challenges and extend patient survival. Its lead product candidate is SIL-204. Silexion collaborates with partners on formulation development and clinical manufacturing to advance its tumor-targeting technology through clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Silexion Therapeutics Corp filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Silexion Therapeutics Corp
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Silexion Therapeutics Corp via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
